Is GPI DBS as effective to STN DBS for tremor control in Parkinson’s disease?
Objective: To compare the benefits of GPI and STN DBS on tremor in Parkinson’s disease (PD). Background: DBS is a highly effective surgical therapy for…The Role of a Social Worker in a Deep Brain Stimulation Multidisciplinary Team
Objective: To characterize the contribution of a social worker (SW) in selecting and managing patients for deep brain stimulation (DBS) surgery. Background: It is common…A comparative study of focused ultrasound unilateral thalamotomy and subthalamotomy for medication refractory Parkinsonian tremor
Objective: Unilateral focused ultrasound (FUS) thalamotomy of the ventral intermediate thalamic nucleus (FUS-Vim) is effective in treating Parkinson’s disease (PD) tremor. FUS ablation of the…Evaluating Adaptive Devices to Assist Eating in Essential Tremor Patients: A Comparative Analysis
Objective: To evaluate the effectiveness of six adaptive devices to mitigate tremor impact while eating in patients with essential tremor (ET), compared to a standard…Variant Ataxia Telangiectasia: A Novel ATM Gene Mutation With Disabling Tremor and Response to Deep Brain Stimulation
Objective: We describe a patient with a novel ATM gene variant presenting with tremor, neuropathy, and late-onset ataxia. Background: Ataxia Telangiectasia (AT) is an autosomal…Suvecaltamide Metabolites Are CaV3 Modulators and Contribute to Pharmacological Effect
Objective: To determine the potency-concentration relationships and combined pharmacological effects for suvecaltamide and its 2 active metabolites (JZZ05000034=M01, JZZ05000035=M02; total active moiety [TAM]). Background: T-type…SAGE-324/BIIB124, an investigational GABAA receptor PAM, for treatment of essential tremor
Objective: KINETIC2 is a multicenter, randomized, placebo-controlled, dose-response Ph2b study evaluating SAGE-324/BIIB124 for treatment of essential tremor (ET). Background: ET is a common movement disorder1,2…Contribution to Efficacy by Active Metabolites of Suvecaltamide in a Preclinical Rat Model of Essential Tremor
Objective: Present the pharmacokinetic/pharmacodynamic (PK/PD) relationship and contribution to anti-tremor efficacy for suvecaltamide and its active metabolites (JZZ05000034=M01, JZZ05000035=M02) in a harmaline-induced rat model of…Once-Daily Suvecaltamide Pharmacokinetics, Safety, & Tolerability–Phase 1, Randomized, Double-Blind, Multiple Ascending Dose Study
Objective: Evaluate the pharmacokinetics (PK), safety, and tolerability of a once-daily (QD) suvecaltamide (JZP385) formulation and its major active metabolites (JZZ05000034=M01, JZZ05000035=M02) in a Phase…The Fazekas scale score and the occurrence of adverse events after MRgFUS thalamotomy, is there a relationship?
Objective: To analyse whether the score on the Fazekas scale (FS) correlates with an increased risk of adverse effects (AEs) after unilateral magnetic resonance-guided focused…
- 1
- 2
- 3
- …
- 15
- Next Page »